Magma Fincorp is now Poonawalla Fincorp after takeover by Serum Institute CEO Adar Poonawalla
Adar Poonawalla is also the Chief Executive Officer of Serum Institute of India, which is manufacturing the Oxford-AstraZeneca vaccine (Covishield) against COVID-19.
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard and Prajavani newspapers. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholding for the Period Ended June 30, 2021
AstraZeneca Pharma India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here ASTRAZENECA PHARMA INDIA LTD. - 506820 - Reg. 34 (1) Annual Report
Pursuant to Regulation 34(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Report of the Company for the financial year ended March 31, 2021 along with the Notice of the Annual General Meeting of the Company scheduled to be held on August 9, 2021 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Annual Report is sent to the members who have registered their email ID with the Company/Depositories. The Annual Report is also available on the website of the Company at www.astrazeneca.com/india. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Notice Of 42Nd Annual General Meeting
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of the 42nd Annual General Meeting of the Company scheduled to be held on Monday, August 9, 2021 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other Audio Visual Means (OAVM). The Notice is being sent to the members of the Company through electronic mode. The said Notice and the Annual Report for the financial year ended March 31, 2021 is also available on the website of the Company at www.astrazeneca.com/india. AstraZeneca Pharma India Ltd - 506820 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- PRATAP RUDRADesignation :- Company Secretary and Compliance Officer
Nepal to get over 1 million doses of Covid-19 vaccine from Japan
Nepal will receive over a million doses of AstraZeneca vaccine from Japan at a time when the country is facing a severe shortage of the jabs.
When should you take AstraZeneca second dose? Here's what evidence says
A study published in Nature reported a single dose of AstraZeneca vaccine induced essentially no Delta virus-neutralising antibodies
COVID-19 Vaccine | Belgium adds Covishield to Green Pass, becomes 15th European country to recognise vaccine
The Belgium Embassy in India on July 9 said the country recognises that Covishield is the Oxford-AstraZeneca vaccine being produced by SII and called the move an important decision in the fight for vaccine equality. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate as per attached details.